# Elizabeth M. Jaffee

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/elizabeth-m-jaffee/

## Facts

| Field | Value |
| --- | --- |
| Citations | 57,617 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 112 |
| i10-index | 343 |
| Last Known Institution | Bloomberg (United States) |
| OpenAlex ID | https://openalex.org/A5050642902 |
| ORCID iD | https://orcid.org/0000-0003-3841-6549 |
| Works | 1,442 |

## Researcher papers

- [Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses](https://scholariq.org/papers/core-signaling-pathways-in-human-pancreatic-cancers-revealed-by-global-genomic/)
- [Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic](https://scholariq.org/papers/development-of-tumor-mutation-burden-as-an-immunotherapy-biomarker-utility-for/)
- [Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer](https://scholariq.org/papers/safety-and-survival-with-gvax-pancreas-prime-and-i-listeria-monocytogenes-i/)
- [A Lethally Irradiated Allogeneic Granulocyte-Macrophage Colony Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Adenocarcinoma](https://scholariq.org/papers/a-lethally-irradiated-allogeneic-granulocyte-macrophage-colony-stimulating/)
- [A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction](https://scholariq.org/papers/a-live-attenuated-listeria-vaccine-anz-100-and-a-live-attenuated-listeria/)
- [Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity](https://scholariq.org/papers/neoadjuvant-cabozantinib-and-nivolumab-convert-locally-advanced-hepatocellular/)
- [Mesothelin Immunotherapy for Cancer: Ready for Prime Time?](https://scholariq.org/papers/mesothelin-immunotherapy-for-cancer-ready-for-prime-time/)
- [Defining the critical hurdles in cancer immunotherapy](https://scholariq.org/papers/defining-the-critical-hurdles-in-cancer-immunotherapy/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)

## Researcher university

- [Bloomberg (United States)](https://scholariq.org/institutions/bloomberg-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.